• Opexa Therapeutics (OPXA) Phase 2b Results of Tcelna for Secondary Progressive MS

       (0 reviews)

    Biotech Forecast
    Clinical and Regulatory
    Event Type: Phase 2b Results
    Timing: Q4 2016
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Autoimmune
    Indication: Secondary Progressive Multiple Sclerosis
    Lead Indication?: Yes
    Treatment Name: Tcelna

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Opexa Therapeutics
    Stock Symbol: OPXA
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://www.opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Launches-Restructuring-Initiative-to-Focus-Use-of-Resources-Ahead-of-Key-Phase-2-Data-Expected-in-Early-Q4-2016/default.aspx
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

    Quote

    Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including for multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it was implementing a restructuring initiative to focus the use of its resources, which should extend the Company's current cash runaway into the first quarter of 2017. The move comes as the Company prepares to complete its Phase IIb clinical trial in Secondary Progressive MS (SPMS) and report top-line data, with the announcement of such data currently expected in early Q4 2016.

     


      Report Event


    User Feedback

    There are no reviews to display.